Its combination with paclitaxel also demonstrated antitumor activity with an ORR of 17.9% and DCR of 67.9% in patients with PTEN-deficient advanced gastric cancer who progressed from first-line therapy (fluoropyrimidine and platinum) in a phase Ib/II trial [140]. This evidence concerns the gene PTEN and gastric cancer.